Is Mangoceuticals, Inc. Common Stock (MGRX) overvalued? · rev $615.9K
Mangoceuticals, Inc. Common Stock (MGRX) is a health information services company listed on US.
This page asks whether Mangoceuticals, Inc. Common Stock (MGRX) looks expensive on cached numbers — not a short thesis.
Latest reported MGRX revenue for 2024-12-31 was $615.9K. Net income was -$8.7M. Revenue was down 15.8% from 2023-12-31 to 2024-12-31. MGRX currently screens at market cap $16.3M.
MGRX currently screens at market cap $16.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MGRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MGRX stock page for the full model, not this heading.
Not investment advice.